AzTrials
AzTrials

Cancer Cachexia (CC)EMC2APANCT06645067

Assessment and Modulation of Energy Balance in Cachectic Patients Using Adapted Physical Activity

An observational study of Cancer Cachexia (CC) and Exercise, run by University of Rennes 2 at 1 site in France.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

1. OBJECTIVE OF THE STUDY The study consists of evaluating resting energy expenditure (REE) and that induced by adapted physical activity (APA) in cachectic patients, compared with those predicted by equations and those of non-cachectic cancer patients. Read more about this study

Who is it for?
Ages 18 to 80 years
Conditions the study is for
Cancer Cachexia (CC), Exercise, Energy Regulation
What is being tested?
Measuring energy balance
How many people
10 participants
Where
1 siteFrance
Study dates
Feb 2025to Dec 2025
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 80 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Cachectic cancer patients: patients who have lost weight significantly in the last 6 months.

Who may be able to join

  • Be at least 18 years old.
  • Have understood the objectives of the study.
  • Have read and signed the consent form.
  • Be affiliated with a social security system.
  • Currently undergoing cancer treatment.

Who cannot join

  • Une fatigue extrême
  • Une anémie symptomatique (hémoglobine ≤ 8 g/dl)
  • Un syndrome infectieux sévère en cours d'évolution
  • Une décompensation de pathologie cardio-pulmonaire
  • La présence de lésions osseuses lytiques du rachis ou des os longs (la contre-indication concerne la mobilisation du membre atteint)
  • Une intolérance au port du masque de l'appareil K5 (Cosmed)

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

France1 site
  • SPORMED

    Rennes, Brittany Region, 35000

    Cindy Richard, PhD, 33 2 99 33 88 44, medical@spormed.fr

Other trials in France

About this study

Official title: Cachectic Cancers and Adapted Physical Activity Assessment and Modulation of Energy Balance in Cachectic Patients Using Adapted Physical Activity

  1. OBJECTIVE OF THE STUDY The study consists of evaluating resting energy expenditure (REE) and that induced by adapted physical activity (APA) in cachectic patients, compared with those predicted by equations and those of non-cachectic cancer patients. We will also seek to identify potential compensations in the level of Physical Activity (PA) and dietary intake during one week of the PA programme.
  2. CONDUCT OF THE STUDY Taking part in this study will in no way affect your treatment at SPORMED; you will undergo the same assessments and carry out the PAA programme in the same way. As a reminder, your treatment at SPORMED consists of an initial assessment session, a 12-week ABS programme and a final assessment session.

If you take part in the EMC2APA study, we will ask you to measure your gas exchange at rest (60 minutes) and during the aerobic part of one of your physical activity sessions. You will perform the effort traditionally targeted during the sessions (constant moderate intensity (60% of your Reserve Heart Rate, equivalent to a perception of the difficulty of the effort of 5-6/10) while your gas exchanges will be measured using a portable, non-invasive measuring device (K5, COSMED®). You will also be fitted with an accelerometric wristwatch.

Read more

In addition to the gas exchange measurements that will take place in the SPORMED structure, we will ask you to fill in a logbook tracking your daily physical activity and your daily food intake. You will also be asked to wear an accelerometer in a belt attached to your hip for 7 days.

Participation in this study is voluntary. There are no restrictions during the protocol.

Read the detailed description

To stabilize patients' weight, it is essential to measure energy expenditure in order to propose appropriate nutritional and physical activity management (Purcell et al., 2016; Vazeille et al., 2017; Barcellos et al., 2021). In clinical practice, nutritional management is often based on predictive equations for end-stage renal disease (ESRD). These predictive equations include parameters such as age, height, weight, and sex. The most widely used is the Harris and Benedict equation, in which 85% of the healthy population has a resting energy expenditure (REE) between 90 and 110% of the predicted value. However, Barcellos et al. (2021) demonstrate that this equation underestimates REE by 648 kcal/day compared to values measured by indirect calorimetry in cancer patients. Predictive equations, therefore, seem obsolete for cancer patients, despite the central role of energy balance in treatment.

Several factors reduce the relevance of these equations and highlight the need for specific measurement of REE and total energy expenditure (TEE). Tumor type, size, and stage influence energy expenditure (Tuccar et al., 2021). A meta-analysis by Nguyen et al. (2016), including 27 studies, shows that REE increases by 9.66 kJ/kg fat-free mass (FFM)/day in cancer patients. REE can increase from 100 to 1400 kcal/day depending on tumor type (Purcell et al., 2016). However, tumor type directs the magnitude and direction of changes in energy metabolism. In a review by Hanna et al. (2023), the lean mass-adjusted REE shows that patients with high gastrointestinal cancers have higher REE than healthy individuals in 6 of the 9 studies, while the other 3 studies reported similar REE (Hanna et al., 2023). Tumors of the lung, head and neck, esophagus, stomach, liver, and pancreas are most affected by hypermetabolism (REE > 110% of predicted values), whereas melanoma, colorectal, and breast cancers show more normal metabolism (90 < REE < 110% of predicted values) or even hypometabolism (REE < 90% of predicted values) (Dempsey et al., 1984; Hanna et al., 2023; Tuccar et al., 2021; Purcell et al., 2016).

Determining the energy expenditure induced by physical activity (PA) in the presence of cachexia would allow for better nutritional management and contribute to further understanding of cancer cachexia management. Moreover, objectively assessing the different components of total energy expenditure (TEE), such as activity energy expenditure (AEE), would validate or challenge the use of predictive equations based on healthy individuals, identifying the specific needs of cachectic patients in terms of TEE and AEE induced by PA. Objective measurement of AEE will be more reliable than subjective estimates using questionnaires, which are prone to over- and under-estimation biases (Purcell et al., 2019). Altogether, this will enable more precise nutritional and PA recommendations for patients.

Objectives

The study aims to evaluate resting energy expenditure (REE) and PA-induced expenditure in cachectic patients compared to values predicted by equations and those in non-cachectic patients. The goal is also to assess potential compensatory effects on PA levels and daily intake during PA sessions.

General Hypotheses

Based on the literature, cachectic patients are expected to exhibit hypermetabolism, with REE values ≥ 110% of the values predicted by equations. Additionally, REE expressed as kcal/day/kg of lean body mass is expected to be higher in cachectic patients compared to non-cachectic patients due to chronic inflammation and tumor-related energy expenditure.

Regarding AEE, no studies have focused on this parameter in cachectic patients. TEE is mostly estimated using approximate predictive equations, with only one study by Moses et al. (2004) addressing TEE in cachectic patients. This study aims to characterize energy expenditure induced by moderate-intensity exercise to adjust nutritional interventions according to patients' PA levels.

Regarding daily PA levels, it is hypothesized that cachectic patients reduce daily PA on PA session days to compensate for energy expenditure (Moses et al., 2004). Additionally, individuals are expected to increase their food intake to maintain energy balance and benefit from symptom reduction provided by PA.

Assessment of Resting and Exercise Energy Expenditure: REE and exercise energy expenditure (EEE) measurements are standardized at the SPORMED facility. If consent is obtained (Consent form in the appendix), data may be transferred to a secure data collection file for analysis. Data will be stored on an external password-protected hard drive and on the Huma-Num University data management server.

Assessment of Eating and Physical Activity Behaviors: Dietary behavior will be monitored over a 7-day period using a nutrition diary. PA behavior (duration and intensity, including vigorous, moderate, light activity, walking, sedentary behavior, and sleep duration) will be measured using a validated accelerometer (wGT3X+) worn at the hip. If consent is obtained, data will be transferred to a data collection file for analysis. Handwritten dietary data will be digitized, and accelerometer data will be extracted. All data will be securely stored.

Variables and Measurement Tools:

Assessment of Resting and Exercise Energy Expenditure: Using the K5 (COSMED®), a portable, non-invasive metabolic system for field and lab tests.

Resting Energy Expenditure (REE): Patients will avoid moderate and vigorous PA for 24 hours before the measurement, as well as a 4-hour fast. No caffeine is allowed for 4 hours and no tobacco for 2.5 hours. During the measurement, patients will rest in a lying position for 30 minutes. The measurement lasts 10 minutes once a stable state is reached (oxygen consumption varies by less than 10%) (Rey, 2018). The room temperature will be kept between 22 and 25°C to limit environmental effects on energy expenditure (Fullmer et al., 2015).

Exercise Energy Expenditure (EEE): Conducted on a treadmill or stationary bike, the measurement includes a 7-minute warm-up, with incremental intensity to reach moderate effort (RPE 5/10 or 60% of max HR), followed by 15 minutes of constant effort. A 2-minute recovery will be included. The data collected will help assess respiratory function and estimate energy expenditure using the Weir equation.

Heart rate, subjective effort perception, and PA "counts" will also be recorded to compare energy expenditure estimates from predictive equations and activity monitors. Dietary intake and appetite will be recorded daily in a nutrition journal, with a 7-day monitoring period.

Study Duration: The number of subjects required was based on Moses et al.'s (2004) study. An estimated 5 patients per group are needed, considering REE and EEE, with a study duration of 7 months.

Being tested
Measuring energy balance
Keywords
Cancer Cachexia, Exercise, Endurance, Energy Expenditure, Food Intake, Physical activity
Medical subject headings
Motor Activity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Measuring energy balanceBehavioural

    The exercise intervention will consist of a personalized and supervised program lasting 12 weeks with two sessions per week, held on Tuesdays and Thursdays at the Sports and Medicine Center SPORMED in Rennes, France.

    Each session will combine endurance and resistance training, commencing with a 6-minute cardiovascular warm-up on ergometers (cycling ergometer or treadmill). This will be followed by 20 minutes at moderate intensity (60-70% of Heart Rate Reserve (HRR)), concluding with a 2-minute recovery period at light intensity. We will measure the resting ED at the start of the programme and the ED during moderate aerobic exercise in the 5th week of APA.

Study groups in NCT06645067
Study groupRoleWhat they receive
Cancer cachectic patientsThis group is made up of patients suffering from cancer cachexia who take part in an APA programme at the medical-sports centre. These are patients who agree to have their energy expenditure measured at rest and during sub-maximal effort, as well as their level of physical activity and diet monitored for 7 days.
Receives: Behavioral: Measuring energy balance

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Exercise energy expenditure

    The measurement will be carried out on a treadmill ergometer and/or stationary bike. The exercise energy expenditure measurement will include a 7-minute warm-up with incremental intensity to reach a work level representing moderate effort in terms of RPE (5/10) or heart rate (60% of maximum heart rate), followed by 15 minutes of constant moderate-intensity exercise. A 2-minute recovery period will be added at the end to avoid abrupt physiological changes. The exercise energy expenditure measurement will take place after a period of familiarization with the cycle ergometer to minimize disturbances caused by stress or technical inefficiency.

    Measured: During an exercise session in the 5th week of the programme.

Secondary outcomes (10)
  1. Resting Energy Expenditure

    Patients will be instructed to avoid moderate and vigorous physical activities for 24 hours prior to the measurement. Additionally, a 4-hour fast will be required, with no caffeine consumption during the last 4 hours and no tobacco use during the last 2.5 hours. During the measurement, patients will lie down for 30 minutes to reduce energy expenditure from previous physical activity. The measurement will then last 10 minutes once a stable state is reached (period during which oxygen consumption varies by less than 10%) (Rey, 2018). The room temperature will be maintained between 22 and 25°C to limit the effects of a cold environment on energy expenditure (Fullmer et al., 2015).

    Measured: During the initial consultation before starting the exercise programme

  2. Physical Behavior : Moderate Physical Activity

    Moderate physical activity will be evaluated using the Steel HR (Withings®) activity monitors and the wGT3X+/GT3X+ accelerometers (ActiGraph®) worn at the waist (Smith et al., 2020), as well as a logbook documenting physical activities lasting longer than 10 minutes.

    Measured: Over 8 days during the exercise program

  3. Dietary Intake and Appetite

    Dietary intake and appetite will be recorded daily in a nutrition journal, which is the reference method (Ortega et al., 2015), and using the SEFI® scale (Simple Evaluation of Food Intake) (Thibault et al., 2021). We will ensure a period of familiarization with the tool before the 7-day measurement period. The journal will allow us to assess appetite perception, meal frequency, quantities consumed, and any potential disruptions. These elements will help identify possible variations related to the completion of APA sessions.

    Measured: For 8 days during the exercise program

  4. Subjective Effort Perception

    Subjective effort perception (RPE) will be assessed using the modified Borg scale ranging from 1 to 10. This scale helps to subjectively assess effort intensity, especially since certain antitumor treatments can alter heart rate responses to exercise.

    Measured: During Exercise Energy Expenditure assessment

  5. Heart Rate

    During both energy expenditure measurements with the K5 (COSMED®), heart rate (HR) will also be measured using a heart rate monitor.

    Measured: During Exercise Energy Expenditure assessment

  6. Physical behavior : Vigorous Physical activity

    Vigorous physical activity will be evaluated using the Steel HR (Withings®) activity monitors and the wGT3X+/GT3X+ accelerometers (ActiGraph®) worn at the waist (Smith et al., 2020), as well as a logbook documenting physical activities lasting longer than 10 minutes.

    Measured: Over 8 days during the exercise program

  7. Physical behavior : Walking duration

    Walking duration will be evaluated using the Steel HR (Withings®) activity monitors and the wGT3X+/GT3X+ accelerometers (ActiGraph®) worn at the waist (Smith et al., 2020), as well as a logbook documenting walking activities lasting longer than 10 minutes.

    Measured: Over 8 days during the exercise program

  8. Physical Behavior : Sitting time

    Sitting time will be evaluated using the Steel HR (Withings®) activity monitors and the wGT3X+/GT3X+ accelerometers (ActiGraph®) worn at the waist (Smith et al., 2020).

    Measured: Over 8 days during the exercise program

  9. Physical Activity Counts

    During both energy expenditure measurements with the K5 (COSMED®) physical activity "counts" will also be measured using a wrist-worn accelerometer. This data will allow comparison of energy expenditure estimates derived from predictive equations and activity monitors (smartwatches).

    Measured: During Exercise Energy Expenditure assessment

  10. Daily Physical Activity Counts

    Daily physical activity "counts" will be measured with the wGT3X+/GT3X+ accelerometers (ActiGraph®). This data will allow comparison of energy expenditure estimates derived from predictive equations and activity monitors (smartwatches).

    Measured: For 8 days during the exercise program

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted16 Oct 2024
  2. Study startFeb 2025 (estimated)
  3. Primary completionMar 2025 (estimated)
  4. Study completionDec 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
10 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06645067
Sponsor's protocol ID
2024-035
Acronym
EMC2APA
Status last verified
Oct 2024
First submitted
14 Oct 2024
Last updated
16 Oct 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

An observational study of Cancer Cachexia (CC) and Exercise, run by University of Rennes 2 at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 16 Oct 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Romane Peyrachon, MD (33 6 09 37 92 45, romane.peyrachon@ens-rennes.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Exercise energy expenditure (time frame: During an exercise session in the 5th week of the programme.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Oct 2024.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in